Research news

UCLH, UCL and spinout company Odin Vision have used artificial intelligence (AI) to help detect early signs of oesophageal cancer in a global first.

Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.

A combination of two drugs could be an effective treatment for the debilitating disease lupus, according to preliminary evidence from a UCLH led trial.

Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 variant first discovered in India are on average lower than those against previously circulating variants in the UK.